The ringing started three weeks after the prescription did. That is the kind of story audiologists and psychiatrists have been hearing from patients for years, anecdotally, without a clear biological explanation. Now a study published in the Proceedings of the National Academy of Sciences offers one. Researchers at Oregon Health & Science University have shown that serotonin, the brain chemical that selective serotonin reuptake inhibitors (SSRIs) are designed to boost, can directly trigger tinnitus-like neural activity in mice by activating a specific pathway into the auditory brainstem. The finding raises an uncomfortable question for the roughly 40 million American adults who take antidepressants, according to federal health survey data: could the most commonly prescribed class of these drugs be fueling phantom sound in some patients?
A direct line from serotonin to ringing
The OHSU team identified a neural projection running from the dorsal raphe nucleus (DRN), the brain’s primary serotonin-producing region, to the dorsal cochlear nucleus (DCN), an early auditory processing hub in the brainstem. When they used optogenetic tools to activate this serotonin pathway, a specific class of neurons called fusiform cells in the DCN began firing at elevated rates. The mice also displayed behavioral signatures consistent with perceiving a phantom sound. The study identified serotonin receptor subtypes involved in this effect, pointing to specific receptors on fusiform cells as mediators of the hyperactivity, a detail that strengthens the case for targeted pharmacological intervention.
That pattern of hyperactivity is not new to tinnitus research. Earlier animal studies established the DCN as a critical node for the condition. In one widely cited experiment, bilateral DCN lesions prevented tinnitus after acoustic trauma in an animal model, showing the structure is not just correlated with ringing but required for it. Separate electrophysiology work demonstrated that increased synchrony and bursting among DCN fusiform cells track closely with tinnitus behavior. What the new PNAS study adds is a chemical trigger: serotonin, delivered through a defined anatomical route, is sufficient on its own to reproduce those firing patterns and the behavioral signs of phantom sound.
Prior laboratory work had already shown that the mouse DCN receives dense serotonergic innervation and that serotonin modulates how DCN neurons respond to input. That foundational research, published in the journal Neuroscience, established the biological hardware. The PNAS paper now shows that hardware in action.
A human clue, but only one
The mouse findings are not the only signal. A peer-reviewed human case report documented tinnitus onset in a patient taking low-dose sertraline, one of the most widely prescribed SSRIs in the United States. The symptom appeared at a dose below the standard therapeutic range, suggesting that even modest increases in serotonin availability can disturb auditory circuits in susceptible people. The authors discussed plausible receptor mechanisms consistent with the animal literature.
Clinicians have reported similar anecdotes for years. Yet a single case report cannot establish how common the problem is, and no large, controlled study has measured tinnitus as a primary outcome in SSRI users. That gap matters. Roughly 25 million American adults experience some form of tinnitus, according to the National Institute on Deafness and Other Communication Disorders. The overlap between that population and the tens of millions on antidepressants is substantial, but no one has systematically quantified it.
What remains uncertain
The central limitation is species translation. Optogenetics allows precise, light-activated control of specific neurons in mice, a technique that cannot be replicated in living human brains. People share the same general structures, including the DRN and DCN, but whether the serotonin projection operates identically in humans has not been confirmed through direct measurement.
Post-marketing surveillance systems do collect spontaneous reports of ear-related side effects from SSRI users, but underreporting is common, and these databases rarely include the detailed audiologic testing needed to separate drug-induced tinnitus from pre-existing hearing loss or age-related changes. The OHSU team’s own institutional summary used cautious language, stating that serotonin-elevating antidepressants “may” exacerbate tinnitus. As of June 2026, based on available literature searches, no randomized trial appears to have been published with tinnitus as a primary endpoint in SSRI users. Searches through repositories such as the National Center for Biotechnology Information suggest the formal evidence base on this question remains thin compared with other documented antidepressant side effects.
What this means for patients and prescribers
The research does not support stopping medication without medical guidance. Untreated depression carries serious risks of its own, including suicide, impaired daily functioning, and worsening physical health. What the findings do support is a specific conversation with a prescribing physician. If tinnitus symptoms appeared or worsened after starting or adjusting an SSRI, and the timeline lines up, dose modification, a gradual switch to a non-serotonergic antidepressant, or the addition of tinnitus-focused therapies such as sound masking or cognitive behavioral therapy may be worth exploring.
For clinicians, the emerging data suggest a refinement to informed consent. When initiating SSRIs in patients who already have tinnitus or significant noise-exposure histories, mentioning a small but biologically plausible risk of symptom worsening is reasonable. Documenting baseline tinnitus status and tracking it over time could help distinguish a drug effect from the natural fluctuation of the condition. When a patient develops new ringing, a structured workup that includes medication review, audiometry, and screening for other causes should come before attributing symptoms to the antidepressant alone.
Why receptor-level research could change treatment
Beyond the clinical caution, the discovery opens a specific line of therapeutic research. If the serotonin receptors on DCN fusiform cells can be selectively blocked without disrupting the mood-regulating effects of SSRIs in cortical and limbic circuits, it may eventually become possible to treat depression and tinnitus at the same time rather than trading one condition for the other. Identifying which receptor subtypes drive the fusiform-cell hyperactivity is the first step; designing compounds with the right selectivity profile and running clinical trials that track both mood and auditory outcomes over months or years will follow.
None of that is imminent. For now, the story of serotonin and tinnitus is best understood as a warning light, not a verdict. The animal data are compelling at the level of circuits. The human data are suggestive but thin. SSRIs remain valuable tools for managing depression and anxiety, with benefits that for many patients will outweigh the uncertain risk of worsening phantom sound. The challenge ahead is to sharpen that risk estimate, identify who is most vulnerable, and find ways to protect the auditory system without sacrificing mental health.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
